Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations
Rodrigo Hoyos-Bachiloglu, … , Mofareh AlZahrani, Raif S. Geha
Rodrigo Hoyos-Bachiloglu, … , Mofareh AlZahrani, Raif S. Geha
Published November 6, 2017
Citation Information: J Clin Invest. 2017;127(12):4415-4420. https://doi.org/10.1172/JCI93486.
View: Text | PDF
Concise Communication Immunology Virology

A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations

  • Text
  • PDF
Abstract

Primary immunodeficiencies are often monogenic disorders characterized by vulnerability to specific infectious pathogens. Here, we performed whole-exome sequencing of a patient with disseminated Mycobacterium abscessus, Streptococcus viridians bacteremia, and cytomegalovirus (CMV) viremia and identified mutations in 2 genes that regulate distinct IFN pathways. The patient had a homozygous frameshift deletion in IFNGR2, which encodes the signal transducing chain of the IFN-γ receptor, that resulted in minimal protein expression and abolished downstream signaling. The patient also harbored a homozygous deletion in IFNAR1 (IFNAR1*557Gluext*46), which encodes the IFN-α receptor signaling subunit. The IFNAR1*557Gluext*46 resulted in replacement of the stop codon with 46 additional codons at the C-terminus. The level of IFNAR1*557Gluext*46 mutant protein expressed in patient fibroblasts was comparable to levels of WT IFNAR1 in control fibroblasts. IFN-α–induced signaling was impaired in the patient fibroblasts, as evidenced by decreased STAT1/STAT2 phosphorylation, nuclear translocation of STAT1, and expression of IFN-α–stimulated genes critical for CMV immunity. Pretreatment with IFN-α failed to suppress CMV protein expression in patient fibroblasts, whereas expression of WT IFNAR1 restored IFN-α–mediated suppression of CMV. This study identifies a human IFNAR1 mutation and describes a digenic immunodeficiency specific to type I and type II IFNs.

Authors

Rodrigo Hoyos-Bachiloglu, Janet Chou, Catherine N. Sodroski, Abdallah Beano, Wayne Bainter, Magdalena Angelova, Eman Al Idrissi, Murad K. Habazi, Hamza Ali Alghamdi, Fahd Almanjomi, Mohamed Al Shehri, Nagi Elsidig, Morsi Alaa Eldin, David M. Knipe, Mofareh AlZahrani, Raif S. Geha

×

Figure 2

The mutant IFNAR1*557next*46 protein retains normal expression, but has impaired signaling.

Options: View larger image (or click on image) Download as PowerPoint
The mutant IFNAR1*557next*46 protein retains normal expression, but has ...
(A) Schematic of wild-type IFNAR1 and the mutant IFNAR1*557next*46 proteins. EC, extracellular domain; TM, transmembrane domain; IC, intracellular domain; NS, previously uncharacterized sequence. (B) Immunoblot of IFNAR1 using lysates from control (C) and patient (Pt) skin-derived fibroblasts. (C) Representative flow cytometric plot (left) and quantification (right) of STAT1 phosphorylation after IFN-α stimulation of patient and control fibroblasts. MFI, mean fluorescence intensity. (D) Representative immunoblot (left) and quantification (right) of STAT2 phosphorylation after IFN-α stimulation of control and patient fibroblasts. *P < 0.05, 2-way ANOVA. (E) Representative immunoblots (left) and percentage of p-STAT1 in the cytoplasmic (C) and nuclear (N) fractions (right) after IFN-α stimulation of control and patient fibroblasts. *P < 0.05, **P < 0.01, Student’s t test. Data shown are from 3 independent experiments, using the proband and 2 controls. NS, not significant.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts